Allogene Therapeutics, Inc. ALLO
- ALLO-316 — Renal Cell Carcinoma Phase 1
- ALLO-329 — Systemic Lupus Erythematosus Phase 1
- ALLO-329 — Idiopathic Inflammatory Myopathies Phase 1
- ALLO-329 — Systemic Sclerosis Phase 1
CD70 (1 companies · 4 programs)
Companies with an active program directed at CD70.